Emerging risk factors and early atherosclerosis indices in subjects with impaired glucose tolerance

Schaan, Beatriz D.; Portal, VL; Ugarte, Mto De; Dias, AA; Hatem, DM

doi:10.1016/s1262-3636(07)70234-3

Cited by 10 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corroborating previous work, 1–4 plasma fibrinogen showed bivariate correlations with virtually all established cardiovascular risk factors assessed in the total study population and to some extent also in the subgroups of men and women. In the adjusted analysis, fibrinogen was higher in women than men and showed a direct relationship to smoking and increased body mass index in all subjects and the male group, while an inverse association with physical activity emerged in men only.…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Nighttime Vagal Cardiac Control and Plasma Fibrinogen Levels in a Population of Working Men and Women

Känel¹,

Thayer²,

Fischer³

2009

Noninvasive Electrocardiol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

“…Fibrinogen is higher in women than in men and in smokers than in nonsmokers 1,2 . Fibrinogen increases with age, higher body mass index, higher blood pressure, dyslipidemia, impaired glucose tolerance, and diabetes 1,2,4 . In contrast, fibrinogen levels are lower with regular physical activity and alcohol consumption 1,2 …”

mentioning

confidence: 99%

Nighttime Vagal Cardiac Control and Plasma Fibrinogen Levels in a Population of Working Men and Women

Känel¹,

Thayer²,

Fischer³

2009

Noninvasive Electrocardiol

View full text Add to dashboard Cite

show abstract

“…Low-grade inflammation is a well-established risk factor of atherosclerosis [18], and this was used to explain microvascular complications frequently occurring in T2D. The oral lipid overload increased CRP and HOMA-IR in IGT subjects [19] suggesting there is an increase in the risk of vascular thrombosis before the diagnosis of diabetes. Evidences indicates that clinical cardiovascular disease can also precede development of T2D [20].…”

Section: Discussionmentioning

confidence: 99%

A Six-Month Supplementation of Mulberry, Korean Red Ginseng, and Banaba Decreases Biomarkers of Systemic Low-Grade Inflammation in Subjects with Impaired Glucose Tolerance and Type 2 Diabetes

Kim

Yoon

Kang

et al. 2012

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

We sought the long-term efficacy of traditionally used antidiabetic herbs in controlling blood glucose homeostasis and low-grade inflammation. Ninety-four subjects with either impaired glucose tolerance or mild T2D were randomized either to treatment arm or placebo arm and received 1 : 1 : 1 mixture of ginseng roots, mulberry leaf water extract, and banaba leaf water extract (6 g/d) for 24 weeks. Oral 75 g glucose tolerance test was performed to measure glucose and insulin responses. Blood biomarkers of low-grade inflammation were also determined. Results found no significant difference in glucose homeostasis control measure changes. However, plasma intracellular adhesion molecule-1 (ICAM-1) concentration was decreased showing a significant between-treatment changes (P = 0.037). The concentrations of vascular cell adhesion molecule-1 (VCAM-1) (P = 0.014) and ICAM-1 (P = 0.048) were decreased in the treatment group at week 24, and the oxidized low-density lipoprotein (ox-LDL) concentration was reduced at week 24 compared to the baseline value in the treatment group (P = 0.003). These results indicate a long-term supplementation of ginseng, mulberry leaf, and banaba leaf suppresses inflammatory responses in T2D.

show abstract

“…AST, ALT, and γGT plasma levels were determined at baseline and every 3 months. The following assessments were completed at baseline, 6 months (T 6 ), and 12 months (T 12 ): body mass index (BMI; overweight, BMI ≥25 and b30 kg/m 2 ; obese, BMI ≥30 kg/m 2 ); abdominal circumference and waist-to-hip ratio; abdominal ultrasonography (severity graded on semiquantitative scale: 0, absent; 1, mild; 2, moderate; and 3, severe) [22]; quality of life (QoL; 36-item short-form health survey (SF-36)) [23]; routine biochemistry tests (blood urea nitrogen, creatinine, bilirubin, total protein, alkaline phosphatase, uric acid, blood cell count, and prothrombin activity); HCV RNA levels (HCV-positive patients); plasma levels of glucose, triglycerides, cholesterol, ferritin, and insulin; and homeostatic model assessment (HOMA) [24]. Cytokines (tumor necrosis factor α (TNF-α), interleukin 10 (IL-10), transforming growth factor β (TGF-β)) and liver fibrosis markers (hyaluronic acid, matrix metalloproteinase 2 (MMP-2), procollagens I and III, tissue inhibitor of metalloproteinases 1 and 2 (TIMP-1 and -2)) were assessed at baseline and at T 12 [25,26].…”

Section: Clinical and Laboratory Assessmentsmentioning

confidence: 99%

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial

Loguercio

Andreone

Brisc

et al. 2012

Free Radical Biology and Medicine

213

147

View full text Add to dashboard Cite

The only currently recommended treatment for nonalcoholic fatty liver disease (NAFLD) is lifestyle modification. Preliminary studies of silybin showed beneficial effects on liver function. Realsil (RA) comprises the silybin phytosome complex (silybin plus phosphatidylcholine) coformulated with vitamin E. We report on a multicenter, phase III, double-blind clinical trial to assess RA in patients with histologically documented NAFLD. Patients were randomized 1:1 to RA or placebo (P) orally twice daily for 12 months. Prespecified primary outcomes were improvement over time in clinical condition, normalization of liver enzyme plasma levels, and improvement of ultrasonographic liver steatosis, homeostatic model assessment (HOMA), and quality of life. Secondary outcomes were improvement in liver histologic score and/or decrease in NAFLD score without worsening of fibrosis and plasma changes in cytokines, ferritin, and liver fibrosis markers. We treated 179 patients with NAFLD; 36 were also HCV positive. Forty-one patients were prematurely withdrawn and 138 patients analyzed per protocol (69 per group). Baseline patient characteristics were generally well balanced between groups, except for steatosis, portal infiltration, and fibrosis. Adverse events (AEs) were generally transient and included diarrhea, dysgeusia, and pruritus; no serious AEs were recorded. Patients receiving RA but not P showed significant improvements in liver enzyme plasma levels, HOMA, and liver histology. Body mass index normalized in 15% of RA patients (2.1% with P). HCV-positive patients in the RA but not the P group showed improvements in fibrogenesis markers. This is the first study to systematically assess silybin in NAFLD patients. Treatment with RA but not P for 12 months was associated with Free

show abstract

Emerging risk factors and early atherosclerosis indices in subjects with impaired glucose tolerance

Cited by 10 publications

References 44 publications

Nighttime Vagal Cardiac Control and Plasma Fibrinogen Levels in a Population of Working Men and Women

Nighttime Vagal Cardiac Control and Plasma Fibrinogen Levels in a Population of Working Men and Women

A Six-Month Supplementation of Mulberry, Korean Red Ginseng, and Banaba Decreases Biomarkers of Systemic Low-Grade Inflammation in Subjects with Impaired Glucose Tolerance and Type 2 Diabetes

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial

Contact Info

Product

Resources

About